• Excellon’s portfolio currently includes active production at the Platosa Mine, with four additional assets in the development or exploration stages
• Excellon saw significant increases in production of lead, zinc and silver at the Platosa Mine from Q4 2019 to Q4 2020
• The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration
• The Company implements a practical management system that addresses the safety, health, security, environmental and community aspects of mining, as per the UN Sustainable Development Goals
• Excellon employs a world-class leadership team with a proven track record of successfully managing and developing similar mineral projects across the globe
• The global market size for precious metals was valued at $193.3 billion in 2020 and is expected to grow to $362.1 billion by 2027

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://ibn.fm/Wdnco). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027. Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5%.

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

• Silver – 355,581 oz – $24.46
• Lead – 2,223,465 lbs. – $0.87
• Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://ibn.fm/l2mfr).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://ibn.fm/UKkSY). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

For more information, visit the company’s website at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• XPhyto Therapeutics Corp. is a life sciences technology accelerator involved in the development of new pharmaceuticals, diagnostic products and psychedelic investments
• XPhyto is preparing a series of clinical pilot studies for four drug candidates this year that could help in treating Parkinson’s disease, epilepsy, anorexia and other neurological conditions
• The company has developed a rapid and highly portable PCR test kit it expects to commercialize this year to provide point-of-care diagnostics, designed for satellite labs to quickly screen for the COVID-19 virus
• Wholly owned subsidiary Vektor, a German drug maker and researcher, plans to build a new commercial drug manufacturing facility this year to help advance XPhyto’s vertical integration plans

Bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is accelerating its mission to advance next-generation drug delivery, diagnostic products and new active pharmaceutical ingredient investment opportunities following a series of successes in 2020 that kept the company productive despite global pandemic conditions.

The goals for the coming year include wholly owned subsidiary Vektor’s construction of a new commercial drug manufacturing facility in Germany, clinical pilot studies for four drug formulation programs XPhyto built up during 2020, taking its COVID-19 PCR test and at least one of its novel, in-house-manufactured biosensor products to market, and the introduction of various psychedelic compounds into Vektor’s drug formulation platforms for the potential treatment of mental health conditions such as depression, anxiety, addiction and trauma-related stress disorder (https://ibn.fm/JgzXk).

“2021 is expected to be a transformative year for Vektor. We will be building on significant momentum from 2020 as we advance our drug formulation, contract development, and psychedelic business,” Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH, stated as part of the company’s announcement. “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.”

XPhyto was founded in 2017 and in 2019 began listing its common shares on the Canadian Securities Exchange, continuing to extend its reach internationally since then. The company’s lead diagnostic product is a rapid and highly portable PCR diagnostic test expected to play a significant role in COVID-19 testing for economically devastated travel industries, as well as other sectors. XPhyto anticipates European commercial (CE-IVD) approval in the first quarter of this year.

Vektor is a German narcotics developer and researcher that has been a leader in the design, testing and manufacture of thin film drug formulations such as skin patches and under-the-tongue strips that deliver active pharmaceutical ingredients (“API”) for over a decade. Its products primarily target pain and other neurological conditions.

XPhyto’s planned drug pilot studies include a Q1 program for Rotigotine, a transdermal patch for Parkinson’s disease patients; a sublingual cannabidiol (“CBD”) strip for epilepsy patients in Q2; a Q3 program for a sublingual tetrahydrocannabinol (“THC”) strip for anorexia and nausea sufferers and an oral CBD / THC strip for people with spasticity difficulties as a result of Multiple Sclerosis.

The “open label, randomized, crossover, two-period, two-sequence, single dose” studies will assess the relative bioavailability of each product and will lead to a final pivotal study and application for regulatory approval if the results are successful.

Potential commercialization and licensing agreements being discussed may lead to enhanced monetization opportunities for the company.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient
• Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment
• Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which creates the tools used in ovarian cancer research
• TumorGenesis has begun to commercialize intellectual property, having received first order for unique ovarian cancer cell culture media in June 2020

In the summer of 2018, 49-year-old Star Dolbier arrived at the University of Maryland Greenebaum Cancer Center with a large mass on her left lung; at the time, the five-year survival rate for her type of advanced lunch cancer was only six percent (https://ibn.fm/iVEw5). However, tests carried out on tiny fragments of tumor DNA allowed her to be treated with a novel drug treatment, virtually eradicating the cancer from her system only 18 months later. In addition to looking at mutations in tumor DNA, oncologists have increasingly begun using laboratory-grown tumors or cancer cells to test the effectiveness of different cancer drugs, thereby helping determine the best course of treatment for a specific individual. Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division.

Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

The use of precision medicine in oncology – a field wherein doctors use insights drawn from laboratory-grown cancer cells and their patients’ DNA to prescribe personalized drug treatments, has seen exponential growth in recent years. Rather than resorting to a one-size-fits-all standard of care, oncologists can prescribe more personalized medicines, with last year seeing the approval of over two dozen such drugs (https://ibn.fm/76SNE); over the next two years, forecasts predict that the number of new personalized treatments will outnumber those developed for the general population.

POAI’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, developing tools (kits, reagents and specialty cell-culture media) to grow tumors and cancer cells in a manner that mimics the patient’s own body.  TumorGenesis’ proprietary Oncology Capture Technology Platform isolates and cultures the patient’s heterogenous tumor sample, providing a much better model of the tumor outside the body (ex vivo). These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans (https://ibn.fm/xhryO). TumorGenesis announced that the division had sold its first order of its unique ovarian cancer cell culture media to a New England-based university seeking to carry out research utilizing laboratory-grown cancer cells.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Hollywall Entertainment Inc. is a technology and broadcasting company with a deep reserve of entertainment media content that it is distributing through its network in the U.S. East and South regions
• Hollywall began rolling out its new, wholly owned brand HW Vision at the end of January to provide cellular equipment and services, streaming media content, live television and on-demand programming
• HWAL’s mission is to use its growing telecommunications prowess as a socio-economic equalizer for rural and underserved minority communities
• The company’s telecommunications networks will also deliver capabilities for telemedicine and tele-education — services that have become valuable during the ongoing global pandemic that has led to limitations on in-person gatherings

Telecommunication and broadcasting company Hollywall Entertainment (OTC: HWAL) has begun rolling out its new wholly owned subsidiary HW Vision to provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. HWAL’s subsidiary HW Vision is advancing its newly acquired company Omnipoint Technology, Inc., a Massachusetts-based telecommunications company, to deliver the services — including content from Hollywall’s large entertainment library and educational programming catalogue — to residential homes and commercial businesses through its network across the Eastern and Southern United States, according to a recent company announcement (https://ibn.fm/s8kAB). HWAL’s growth is fueled by a dedicated mission to level socio-economic playing fields through telecommunication services to underserved communities and minority populations. The company’s mission supports the growth of U.S. minority business enterprises (“MBEs”) owned and operated by African Americans, Asian Americans, Hispanic Americans, Native Americans, and Pacific Islanders and their communities. “We will faithfully remain steadfast and committed to our work to deliver on our promised mission of Fiber to the People (TM), inviting a beacon light of hope to inspire those that live within the fringes of some (of) our nation’s most devalued and disenfranchised communities, who continue to endure the suffrages from the lack of internet access symbiotic of the ever-widening digital divide,” Hollywall President and CEO Darnell Sutton stated in the company announcement. “We as a nation of all races, color, and creed must come together in unity and take a firm stand against all racial and social injustices, or sadly, we will remain enthralled within the midst of one of the greatest challenges of a spiraling disparity that will no doubt eventually adversely affect an entire new generation.” Another HWAL subsidiary, Hollywall Development Company (“HWDC”), specializes in the design, creation and management of 5G fiber networks. Its initiatives and investments include broadband and 5G networks, Internet-dependent products and services (“IOT”), smart city technologies, telemedicine, tele-education and waste management. Telemedicine and tele-education have been particularly useful services during the past year as the global COVID-19 pandemic has led to a variety of “distancing” standards designed to reduce the spread of viral infection but that have also prevented schools, businesses and health clinics from operating in the freely accessible, in-person reception manner that has historically served as the nuts and bolts model for commerce. The company also continues to expand its U.S. Governmental Affairs and Lobby Division portfolio as part of the effort to develop broadband networks nationwide with the help of national public works companies and federal agency partners. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• TAAT Lifestyle & Wellness is focused on serving the current smokers’ market, offering its target audience the opportunity to keep the smoking experience that they enjoy with no nicotine and no tobacco
• The company’s proprietary product, TAAT Beyond Tobacco, undergoes a patent-pending refinement process
• The product was successfully launched in Ohio during Q4 2020, with nearly one-third of the visitors to the TryTAAT webpage requesting their samples by mail
• TAAT Lifestyle & Wellness management is highly experienced in the tobacco industry, including roles with larger businesses like Philip Morris International
• The global tobacco market was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form. These numbers provide a foundation of several hundred million legal-aged smokers worldwide who may turn to nicotine- and tobacco-free products such as TAAT
• TAAT Lifestyle & Wellness Ltd. is offering a product that could significantly change how current legal aged smokers quit smoking thanks to its replicated sensory elements mimicking the traditional cigarette experience

TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco. The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique. This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://ibn.fm/b9lMP). TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada. TAAT(TM) TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG. The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

• Visual– the nearly identical product packaging and enhanced smoke volume
• Auditory– the “crackling” sound of the base material when it is ignited
• Smell– when burning, TAAT emits a tobacco-like scent
• Taste– the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
• Touch– TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

• Price– TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers
• Experience– TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy
• Branding/Packaging– TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes. Market Outlook In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://ibn.fm/MhLpq).  In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes. The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://ibn.fm/oWLFk). TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year. Management Team Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto. Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law. Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company. For more information, visit the company’s website at www.taatglobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• The current standard for bladder cancer visualization, white light, is over three decades old and used in 95% of the bladder cancer surgeries
• The recurrence rate of bladder cancer is more than 50% due to the inability to see clear margins in the white light surgical standard for visualization
• Imagin Medical Inc.’s proprietary i/Blue(TM) System changes the way that surgeons visualize bladder cancer with side-by-side imaging of white and blue light pictures on one screen
• Blue light procedures are capable of reducing recurrence rates by 12-43% depending on the type, stage, and grade of bladder cancer
• The global bladder cancer market is expected to reach $4.71 billion in 2026

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company’s current focus is bladder cancer, the most expensive cancer to treat due to a high recurrence rate (50 percent), leaving approximately 600,000 people in the United States living in fear that their cancer will return.

The current standard for visualizing bladder cancer is white light during cystoscopies, a three-decade old technology and used in more than 95 percent of interventions. Cystoscopies use white light to visualize the tumor on the bladder’s surface. The problem with the white light is that it is only effective for the cancerous tumors that protrude above the bladder wall.  For the flat margins, it is almost impossible to see them with white light alone.

The American Urology Association recommended the use of blue light, combined with an FDA approved fluorescing imaging agent, to their guidelines for bladder cancer detection. Blue light, used with contrast agents, can help with easier detection of flat tumors and the margins for more successful resection. Depending on the type of bladder cancer, blue light cystoscopies can help reduce recurrence rates by 12-43 percent as enhanced visibility allows for a more efficient resection of tumors (https://ibn.fm/hS4jW).

However, the blue light used by surgeons in the field today is only available from one scope manufacturer, and doesn’t show images in real time, requiring surgeons to constantly switch between white and blue light during interventions.

Imagin Medical’s i/Blue(TM) Imaging System can correct the limitations of today’s white and blue light cystoscopy procedures. The innovative technology allows the surgeon to see the real-time white light image, side-by-side with the blue light image on the screen simultaneously during a procedure. Additionally, the technology is highly versatile and can be attached to most endoscope model available on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.

Bladder cancer is the sixth most prevalent type of cancer in the United States. It is estimated that the number of new bladder cancer cases in 2020 reached 81,400, which accounts for 4.5% of all new cancer cases. The estimated number of deaths in 2020 equaled 17,980, accounting for 3% of all cancer deaths (https://ibn.fm/Sm3h5). According to Verified Market Research, the global cancer market was valued at $3.43 billion in 2018 and is expected to reach $4.71 billion in 2026 (https://ibn.fm/6okPh).

Led by a management team with significant experience in the market, both in medical device implementation and MIS, Imagin Medical is confident that its technology has the potential to revolutionize the current standard of care for bladder cancer patients, positioning the company as a leading provider of effective solutions in the vast market of bladder cancer visualization.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Using BRSF’s EEG products, Marketing Brainology was able to identify the most effective method for dispensing COVID-19 messaging
• Collected invaluable data for the current pandemic as well as how to navigate the future

Brain Scientific (OTCQB: BRSF) is focused on developing innovative and proprietary medical devices and software. As the company works to modernize brain diagnostics through cutting-edge tech, it has also collaborated with Marketing Brainology, a neuromarketing firm that uses neuroscience to understand consumer behavior.

In 2019, Marketing Brainology conducted a test to measure Super Bowl advertisements’ impact using the NeuroCap, disposable EEG headset and NeuroEEG, a 16-channel EEG amplifier and software along with in-depth interviews and eye-tracking software; the study was repeated in 2020, confirming that one size does not fit all with consumers. The company also released a video that shows the NeuroCap in action as Marketing Brainology studies consumers’ emotional reactions to these ads (https://ibn.fm/warLu).

Marketing Brainology uses neuroscience to identify decision triggers in the human brain. The same methods used to identify Super Bowl ads’ impact was used to determine the most effective messaging for dispensing COVID-19 messaging in 2020. Inspirational messages, particularly those from doctors and nurses, were better received than alarming messages. In fact, negative dramatic messaging was more likely to be tuned out than the empathetic and inspirational messages of hope.

“These methods unlock doors regarding human nature when a crisis is at hand,” said Marketing Brainology president Michelle Adams (https://ibn.fm/An0pL). “This information supplies invaluable data for the current situation we face as well as how we should navigate the future.” Brain Scientific interviewed Adams regarding Brainology’s experience using the Brain Scientific’s EEG equipment to measure consumers’ brain activity and emotional response.

Adams pointed out several features that were important in choosing this partnership. These features include medical-grade equipment; easy setup, which is crucial for subjects with long and thick hair; not clunky or pricey; and continued dedication toward improvement

“Overall, what I admire about MemoryMD’s (a subsidiary of Brain Scientific Inc.) team is that they took the time to develop the technology,” stated Adams. “I am sure they could have rushed to market a lot sooner, but they went through their own checks and balances. Because they are medically driven… I have 100% faith that [BRSF’s] technology is top of the line — and the medical community would not accept something less. For what we need it is more than enough in terms of quality and accuracy.”

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• U.S. miners — and mining industry — will help drive country’s post-pandemic recovery
• Biden sees the “importance of bringing home critical supply chains so that we aren’t dependent on other countries in future crises”
• UUUU committed to play key role in that plan on critical minerals

The new Joe Biden White House agenda “rests on a foundation provided by the nation’s nearly 600,000 miners — miners and a mining industry ready to do their parts to help drive America’s post-pandemic recovery,” according to recent NWITimes article (https://ibn.fm/cSMsr). That agenda is welcomed by U.S. mining companies, including Energy Fuels (NYSE American: UUUU) (TSX: EFR), the country’s largest producer of uranium, who also expects to become a producer of an intermediate rare earth element (“REE”) product in early 2021. According to the article, Biden’s website states: “We’ve seen the importance of bringing home critical supply chains so that we aren’t dependent on other countries in future crises.” The article goes on to point out that “reinvigorating domestic mining and bringing home critical mineral supply chains should be top priorities of that effort. Mobilizing American manufacturing and innovation to ensure that the future is made in America must begin with mobilizing the nation’s miners. The innovative products of tomorrow — be they 5G smartphones, robotics or electric vehicles (‘EVs’) — all rely on a massive number of minerals and metals that stretch the full breadth of the periodic table. Just as the world remains firmly in an era of energy addition where global energy demand is expected to jump 50% by mid-century, we are now in the most mineral and metal intensive era in human history.” Energy Fuels is committed to playing a key role in that era. In 2018, the U.S. government identified 35 minerals as being critical to the country’s national security and economy, including rare earths, uranium and vanadium which the company produces. “For 31 of these 35 minerals, the U.S. imports more than half of our requirements,” observed Energy Fuels president and CEO Mark S. Chalmers (https://ibn.fm/MR2Ud). “And, for 14 of these 35 minerals, the U.S. is effectively 100% dependent on imports. These minerals are needed for aerospace, computers, cell phones, electrical generation and transmission, renewable energy systems and batteries, and advanced electronics. This is an unacceptable situation for a superpower like the United States. “Energy Fuels stands ready to do our part in bringing uranium, vanadium and rare earth element processing and production back to the United States,” Chalmers continued. “We have led uranium industry efforts in Washington DC over the past three years to bring the issue of mineral supply chain security to the forefront.” In 2018, Energy Fuels and Ur-Energy Inc. together submitted a petition for relief under Section 232 of the Trade Expansion Act of 1962 from Imports of Uranium Products that Threaten National Security (https://ibn.fm/9klO7). The petition pointed out that, despite uranium’s critical role in supporting carbon-free electricity and national defense, imports of cheap, foreign state-subsidized uranium have swelled in recent years to the point that domestic suppliers currently provide less than 1% of the nation’s demand. This effort culminated in December 2020, with a spending bill passed by both houses of Congress and signed by the president, allocating $75 million to create a strategic national uranium reserve to be supplied with uranium mined in the U.S. by companies such as Energy Fuels. Energy Fuels is the leading U.S.-based uranium mining company, supplying U₃O₈ to major nuclear utilities. The company also produces vanadium from certain of its projects, and it was the nation’s largest producer of this critical minertal in 2019. Importantly, Energy Fuels expects to begin production of a mixed rare earth carbonate in early 2021, meaning the company will be producing commercial quantities of a rare earth produce at a stage more advanced than any other U.S. company. Headquartered in Denver, Colorado, the company holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is truly a one-of-a-kind U.S. facility. It is the only conventional uranium mill operating in the country today, and it has a licensed capacity of more than 8 million pounds of U₃O₈ per year. The mill also produces vanadium, and it is about to produce rare earths. The mill also recycles uranium and vanadium, saving the world’s resources and avoiding carbon emissions. During its history, the mill has recycled enough uranium that, if converted into nuclear fuel, would provide the same amount of electricity as the coal contained in a train that stretched from Los Angeles to New York City and back again. The mill has also recycled the amount of vanadium that would be contained in the steel required to build four and a half Golden Gate Bridges. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• California-based PowerTap Hydrogen Fueling Corp. has signed a definitive agreement with the companies collectively comprising the Andretti Group to locate PowerTap’s hydrogen station technology at select Andretti properties
• The Andretti Group will further help market PowerTap’s technology to third-party chain retailers, major oil companies and independent stations through the Andrettis’ deep network of automotive industry connections
• Clean Power Capital Corp., based in British Columbia, Canada, is a major investor in PowerTap, holding 90 percent equity interest as part of its mission to help build holdings in the health and renewable energy industries
• Clean Power announced in December that its appearance on the Canadian Securities Exchange has been enhanced by listing on two of the CSE’s indices — the CSE Composite Index (R) and the CSE25 (TM) index — and that the company is examining the possibility of uplisting to the NASDAQ exchange in the United States

Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) recently announced a landmark definitive agreement between its investee company, PowerTap Hydrogen Fueling Corp. and the Humboldt Petroleum, Inc., Peninsula Petroleum, LLC, and Colvin Oil I LLC (dba GP Energy) companies that collectively are identified as “the Andretti Group.” PowerTap is a technology-developing business determined to build a large network of hydrogen fuel stations that will help Americans embrace hydrogen as a clean energy alternative to petroleum for vehicles including long haul Class 8 trucks and cars. The company intends to develop a network across the United States in a phased approach, beginning with a launch of 500 outlets in California that use its onsite steam methane reforming (“SMR”) hydrogen production and dispensing modular units. The Andretti Group agreement will allow PowerTap to install its 1,250-kilogram hydrogen production and dispensing stations at certain California properties owned by the Andretti Group, while the Andretti Group works to exclusively introduce and distribute PowerTap to its deep network of third-party major oil companies, chain retailers, cardlock operators and independent fueling stations under a retailer “revenue share” model, according to the Jan. 26 announcement (https://ibn.fm/qtIyC). PowerTap will infuse an initial $1.25 million to the Andretti Group initiative to enable the Andretti / PowerTap initiative to become operative quickly. “Given our long family lineage around the automobile, we are thrilled to be on the vanguard of new transportation technology — especially in this very exciting and promising area of Hydrogen Fuel Cells,” a statement issued by Andretti Group Chairman Mario Andretti and his partner/son Michael Andretti reads. “We are always energized at being first in the application of innovative technologies. We relish the prospect of leading America’s move to cleaner and more efficient energy.” Western Canada-based Clean Power has 10 investments in a variety of sectors and successfully held nearly $120 million in investments last year, when it gained a 90 percent interest in PowerTap through an equity investment in the company’s clean energy operation. Clean Power’s corporate focus is on the health and renewable energy industries, aiming to help a select set of private and public companies grow to meet their potential. The Andretti Group will also provide PowerTap with services including tactical and strategic planning, network development, real estate support, project management, account management and various “run and maintain” support projects in connection with the fueling stations. PowerTap believes its technology has the potential to supply a cleaner fueling process than technologies dependent on large amounts of electricity to produce hydrogen, and that it can be more cost-effective than hydrogen produced offsite from the fueling stations. Clean Power’s entry on two Canadian Securities Exchange indices — the CSE Composite Index (R) and the CSE25 (TM) index — is designed to help its holdings grow, and the company announced in December that it has formed a strategic committee to examine the possibility of listing common shares on the NASDAQ exchange in the United States to further improve its attractiveness to investors (https://ibn.fm/AA9Od). For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• Not all face masks equally effective; high-filter masks proven most powerful
• Doctors call for national hi-fi mask initiative to widely distribute masks to each household
• United Medical offers high-filter masks; positioned to capitalize on broader recognition of hi-fi masks

Not all masks are created equals, states a recent Stat article, which underscores the importance of high-filtration (hi-fi) masks. The article, titled “Along with vaccine rollouts, the U.S. needs a National Hi-Fi Mask Initiative,” states that hi-fi masks such as N95 masks are the most effective in protecting against COVID-19 (https://ibn.fm/l3FJc). As a company distributing a comprehensive line set of COVID-19 products, including hi-fi masks, United Medical Equipment Business Solutions Network (“UMEBSNI”) is positioned to benefit from the growing recognition of the importance of this type of superior protection. That article claims that, although the first COVID-19 vaccines are now being distributed, masks remain essential since it will likely be months before enough people are vaccinated. In addition, the threat of the global spread of the more-infectious variant of the virus is a possibility until the vaccine effectiveness is determined. Against this still uncertain backdrop, masks can help prevent as many infections and save as many lives as possible. However, although most masks offer some level of protection, many of them, including the most commonly used cloth and surgical masks, only partially filter out the small COVID-19-spreading particles. A recent study demonstrated that high-filtration masks such as N95 offer the best protection against these small particles. The authors of the article — two of whom spent months treating COVID-19 patients without getting infected, which they attribute to the N95 masks they wore — call for a national hi-fi mask initiative to widely distribute masks proven to provide more protection from virus particles, thus reducing the spread of the virus. In the article, they urge the new Biden administration to invoke the Defense Production Act to scale up the production of certified hi-fi masks immediately and speed up the development of new designs. Under this scenario, a set of masks would be mailed to each U.S. household every month. Although it may appear expensive, authors claim that this strategy, followed in some countries, will ultimately cost less than the pandemic’s toll on lives and the economy. As a trusted supplier of personal protective equipment, including hi-fi masks, United Medical Equipment is poised to capitalize on the growing wider recognition of the importance of this type of mask. Although COVID-19 vaccines are finally being rolled out, the global pandemic is not yet over, and United appears quick to adapt to market needs requiring ongoing access to personal protective equipment (“PPE”). The company offers a separate product line dedicated entirely to the needs of patients and health-care providers whose lives and work are impacted by the COVID-19 pandemic. That line includes a range of hi-fi masks as well as other products including testing kits, sanitizers, gloves, face shields, thermometers and hoods. Although shortages of PPE have eased somewhat compared to the start of the pandemic, many healthcare organizations are still concerned about maintaining their supply (https://ibn.fm/VK07P) as these products remain in high demand. As part of its efforts to provide essential PPE products during the pandemic, United Medical Equipment Business Solutions Network Inc. remains dedicated to serving this growing market need. For more information, visit the company’s website at www.UnitedMedSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed